Clinical Imaging and Case Reports

Open Access

A severe case of pathology with concomitant use of avapritinib and antidiabetic drug requiring nascent dialysis

Ahmet Erhan*, Berk Kilinc

Baskent University School of Medicine, Alanya Practice and Research Center, Antalya, Turkey

Corresponding Author:
Ahmet Erhan,
Baskent University School of Medicine, Alanya Practice and Research Center, Antalya, Turkey,
Email: erhanahmet@atsu.edu

Article Type: Case Report
Received Date: October 15, 2021
Accepted Date: October 19, 2021
Published Date: November 30, 2021

Abstract:

Introduction: Avapritinib (Ayvakit), a amino acid enzyme matter (TKI), has been recently approved for the treatment of adult patients with unresectable or pathologic process canal stromal neoplasm (GIST) WHO have a platelet-derived protein receptor alpha (PDGFRA) DNA eighteen mutation. New therapeutic agents for malignancy, specifically TKIs, have allowed for major advances in treatment choices. Case Report: A 56-year-previous male with past case history vital for GIST of the abdomen, WHO was recently started on a brand new trial medication ayvakit, given with nausea, vomiting, and feeling unwell. His initial laboratory work was exceptional for blood sugar level of nineteen mg/dL, creatinine of ten.41 mg/ dL, metallic element of four.3 mmol/L, ion gap of forty one mmol/L, and to dehydration, thus requiring vasopressors for a brief length. Among the patient's home medications, it's of significance to say Glucophage as a daily medication. He emergently underwent haemodialysis for severe pathology, with vital improvement in his clinical standing. Conclusion: pathology will occur as a aspect result of medical aid or synergistic result of multiple medications. Avapritinib usage in conjunction with medications that ar noted to own potential to cause pathology, like Glucophage, has to be cautiously administered. Understanding the potential aspect effects of latest medical aid together with the patient's established medications will facilitate the popularity of potential causative relationships.

Keywords: pathology, Avapritinib, Dehydration, Metformin

INTRODUCTION

Gastrointestinal stromal tumors (GISTs) ar rare soft tissue sarcomas of the canal, with most carrying preserved driver mutations within the amino acid enzyme receptors KIT or platelet-derived protein receptor alpha (PDGFRA) [1]. KIT may be a type-3 receptor amino acid enzyme (TK) that's ofttimes mutated at DNA eleven or seventeen in an exceedingly form of cancers [2]. The drug avapritinib (Ayvakit) was approved by the Food and Drug Administration on Gregorian calendar month nine, 2020 for adults with unresectable or pathologic process GIST harboring a PDGFRA DNA eighteen mutation, together with D842V mutations [3]. This medication is specifically indicated for unresectable or pathologic process GIST tumors with the expressed mutations. The approval of this medication for treatment was supported knowledge from the single-arm, open-label NAVIGATOR trial [3]. supported the information from the NAVIGATOR trial, exposure-response relationships for any major adverse reaction were ascertained at higher exposures with a quicker time to onset for adverse reactions with increasing avapritinib exposure [3]. The pharmacological medicine of this medication is understood to own median time to peak concentration starting from two.0 to 4.1 hours following single doses of avapritinib thirty to four hundred mg [3].

With most plasma concentration (Tmax) of 2–4 hours, avapritinib is chop-chop absorbed and exposure will increase linearly with increasing dosages. the foremost common according adverse reactions for this medication are edema, nausea, fatigue/asthenia, vomiting, abdominal pain, constipation, and symptom. within the early part trial of this medication, avapritinib was noted to be well-tolerated with most adverse events scored as either grade one or two mistreatment doses between thirty and four hundred mg daily [4]. There ar according interactions between ayvakit and alternative medications like sturdy and moderate CYP3A inhibitors as these drugs' interaction will increase avapritinib plasma concentrations. There ar recommendations for medication dose reduction for patients WHO cannot avoid
a moderate CYP3A matter.

Prior findings have shown that DNA eleven mutations predominate in GISTs. Avapritinib may be a amino acid enzyme matter (TKI) that demonstrates clinical activity in malignancies harboring DNA seventeen mutations. Recently, a study targeted on the budget impact of mistreatment avapritinib for treatment of unresectable or pathologic process GIST showed token budget impact to a North American country health set up, because of the tiny patient population and price savings from reduced post-progression prices [2]. canal stromal tumors represent one amongst the exceptional cases of solid tumors wherever the biology is vital to know for medical medical aid. Indeed, TKIs ar customary|the quality} medical aid for KIT-mutated GISTs and ar expected to be standard for PDGFRA-mutated ones further.

Pertaining to this case report, it's vital to focus on a crucial adverse event of Glucophage, that is drinkable pathology that if truth be told influences treatment ways in kind two diabetes [5].

Here we tend to gift a case of a patient WHO given with severe pathology thought to be from Glucophage toxicity secondary to aspect effects from a freshly started medication.

CASE REPORT

A 56-year-old male with past case history vital for GIST of the abdomen, hyperpiesia, kind two diabetes, embolism, and bilateral lower extremity deep vein occlusion (DVT) on apixaban, benign ductless gland cardiovascular disease, oesophageal reflux sickness, associated lipemia was transferred from an far facility for any management of acute kidney disease, symptom, and metastasis failure. The patient had originally given to the far facility with complaints of shortness of breath, nausea, vomiting, and overall feeling poorly since beginning avapritinib period of time previous.

At far facility, the patient's initial laboratory work was exceptional for blood sugar level of nineteen mg/ metric capacity unit, creatinine of ten.41 mg/dL, metallic element of four.3 mmol/L, ion gap of forty one mmol/L, and blood gas with pH of six.707, pO2 163 mmHg, pCO2 fourteen mmHg, and HCO3 {of two|of two} mmol/L on 2 L of nasal tube gas. important signs vital for physiological state of thirty four.8 □C, arrhythmia with rate of fifty beats per minute, rate of respiration of thirty breaths per minute, and pressure average 170/80 mmHg. The patient was desperately given associate amp of D50 with optimum response. hydrogen carbonate and blood vessel fluid resurgence were initiated, and patient was transferred to our facility. Of significance, the patient was ab initio neurologically intact on presentation however step by step became confused. because of imminent metastasis failure, he needed endotracheal intromission before transfer.

The patient's home medications enclosed apixaban five mg BID, ferric salt 325 mg daily, gabapentin one hundred mg BID, Glucophage one thousand mg BID, Lopressor salt twenty five mg BID, pantoprazole forty mg daily, Pravachol twenty mg daily, amlodipine five mg daily, painkiller eighty one mg daily.

The patient bit by bit needed accumulated dosages of vasopressors, specifically ADH and adrenaline. Despite the shock standing, he was able to tolerate aborning qualitative analysis with important improvement in his creatinine level from ten.3 to 4.64 mg/dL. once the primary session of qualitative analysis, carbonate improved from admission price of 2–17 mmol/L. Laboratory work improved with the assistance of volume

improvement via dialysis, and therefore the patient was monitored closely while not qualitative analysis for clinical improvement. With the development within the patient, he was able to be extubated shortly once presentation to our facility. once forty eight hours within the medical aid unit, he was able to be transferred to the overall medical floor.

After the initial admission qualitative analysis session, the patient's urinary organ perform was improved, however, that wasn't adequate as reportable by the medicine team. Tunnel tubing for qualitative analysis was placed, and therefore the patient received his second qualitative analysis session seventy two hours once admission. Throughout patient's hospitalization, contact was created habitually together with his medical medical specialist at his tertiary center for recommendations on his treatment. For the length of his hospital keep, avapritinib was control associate degreed plans were created to make your mind up on an applicable programme for the patient's GIST treatment as patient. With clinical and symptomatic improvement, the patient was able to be discharged to home with plans for follow-up with medicine, oncology, and first care of knowledge, rewriting the work critically for vital intellectual content, Final approval of the version to be printed, comply with be in control of all aspects of the add guaranteeing that queries associated with the accuracy or integrity of any a part of the work area unit suitably investigated and resolved.

Change in his home medication list enclosed discontinuing Glucophage and avapritinib till follow-ups consequently. Shortly once discharge from the hospital, the patient had associate degree patient follow-up together with his medical medical specialist. throughout the follow-up visits, it had been discovered that the patient continuing to try and do well with glorious craving and really rare nausea. He had needed one qualitative analysis session once his hospital discharge, however luckily his urinary organ perform bit by bit recovered to the purpose that his qualitative analysis tubing was removed a month once discharge. Given patient's clinical improvement, his avapritinib was restarted however at a lower dose and solely 3 times weekly. His home medication of Glucophage wasn't restarted, and he continuing to observe glucose levels with a haemoprotein A1c of six.2%.

Further follow-up with medical specialty on the down indefinite quantity of avapritinib showed the patient was tolerating the prescribed indefinite quantity. He had no a lot of episodes of nausea, vomiting, fatigue, or channel distress. The indefinite quantity of his medication was slowly up titrated to one hundred mg once daily. The patient continues to follow with medical medical specialty closely, and no substitute for patient's home Glucophage has been started nevertheless given his controlled home glucose measurements with way modifications.

DISCUSSION

The TKIs have radically modified the treatment course of KIT-driven GISTs. Approved second-line and third-line medical therapies area unit drawn by the TKIs sunitinib and regorafenib, severally [6]. the link between Glucophage and beverage pathology is complicated, which means that the utilization of the drug is also causative, co-responsible, or simultaneous. dialysis ought to consistently be performed in severe varieties of beverage pathology, since it provides each symptomatic and etiological treatment (by eliminating suckle and metformin) [4]. Glucophage will increase plasma suckle levels in an exceedingly plasma concentration-dependent manner by inhibiting mitochondrial metastasis preponderantly within the liver [7]. Typically, the mixture of elevated plasma Glucophage concentrations (e.g., in urinary organ impaired patients) and a secondary event that disrupts suckle production or clearance (e.g., infection or hypoperfusion) area unit necessary to cause Glucophage associated beverage pathology (MALA) [7].
In the case of our patient, he was diagnosed with GIST of the abdomen positive for CD eleven7 with KIT DNA 11 mutation in November 2007. Since that year till 2020, he had been treated with multiple immunotherapies together with imatinib. amendment in treatment was performed once there was a rise within the size of the viscus mass whereas on imatinib. The patient was later started on sunitib while not important clinical improvement. He was then switched to regorafenib however sadly increase in liver mass was noted. He was switched to nilotinib medical care supported activating KIT DNA eleven mutation, however once 2 years of medical care, once more increase in liver metastasis to portal bodily fluid nodes was noted. He was switched to

dasatinib, however tough aspect effects of inflammation and chronic poor wound healing. once one year of treatment with dasatinib and poor clinical progress with accumulated metastasis, the patient was started on avapritinib three hundred mg daily in February 2020.

The interaction between avapritinib and bound medication has been studied to date, together with antimycotic (a sturdy CYP3A inhibitor), Rimactane (a sturdy CYP3A inducer), and efavirenz (a moderate CYP3A inducer). Thus far, the interaction between avapritinib and Glucophage has not been studied to our knowledge; this adds to the individuality of this case as unknown interactions may have major adverse outcomes. In alternative words, no interactions of risk level A or bigger area unit known between avapritinib and Glucophage.

A crucial potential aspect result of avapritinib includes nausea and instinctive reflex, that may have diode to dehydration within the setting of patient taking metformin; ultimately, this method may have diode to Glucophage toxicity as a results of kidney disease. within the case of our patient, one may argue the speculation that his malignancy treatment had the aspect effects of nausea and instinctive reflex, ultimately resulting in dehydration. though this dehydration is probably going the explanation for the patient's Glucophage toxicity, the severity of patient's pathology is price discussion for investigation. To date, there is no available literature among the interaction between avapritinib and metformin. Furthermore, upon review of literature, there are no reported direct interaction between chemotherapeutic agents and metformin. Upon further literature review, acidosis is not known to be a side effect of avapritinib.

CONCLUSION

Diabetes is above all a vascular disease and metformin is a vascular drug with antidiabetic properties. The possible synergistic effect of avapritinib and metformin, or rather more specifically the side effects, in causing toxicity is yet to be studied and potentially can be an avenue of further research.

REFERENCES

1. Mei L, Smith SC, Faber AC, et al. Gastrointestinal stromal tumors: The GIST of precision medicine. Trends Cancer 2018 4(1):74–91.
2. Winger BA, Cortopassi WA, Ruiz DG, et al. ATP-competitive inhibitors midostaurin and avapritinib have distinct resistance profiles in exon 17-mutant KIT. Cancer Res 2019:79(16):4283–92.
3. FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation. [Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation]
4. Lalau JD. Lactic acidosis induced by metformin: Incidence, management and prevention. Drug Saf 2010;33(9):727–40.
5. Blough B, Moreland A, Mora A Jr. Metformin-induced lactic acidosis with emphasis on the anion gap. Proc (Bayl Univ Med Cent) 2015;28(1):31–3.
6. Gilreath JA, Tchertanov L, Deininger MW. Novel approaches to treating advanced systemic mastocytosis. Clin Pharmacol 2019;11:77–92.
7. DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: Current perspectives on causes and risk. Metabolism 2016;65(2):20–9.8.
8. Elmezughi K, Ekpebegh C. Metformin-associated lactic acidosis treated successfully by peritoneal dialysis in a resource limited setting: Case report. Pan Afr Med J 2019;32:112.
9. Park B. Ayvakit approval for GI stromal tumor with PDGFRA mutation. 2020. [Available at: https://www.gastroenterologyadvisor.com/general-gastroenterology/ayvakit-approval-for-gi-stromal-tumor-with-pdgfra-mutation]
10. Proudman D, Miller A, Nellesen D, et al. PCN84 budget impact analysis of ayvakit (avapritinib) in patients with gastrointestinal stromal tumors and a PDGFRA exon 18 mutation. Value in Health 2020;23(Suppl 1):S38.